Marcin Czerwinski/LinkedIn;
Radoslaw Kaczmarek/LinkedIn
Mar 28, 2026, 17:01
Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
Marcin Czerwinski, Professor at Hirszfeld Institute of Immunology and Experimental Therapy, shared a post on LinkedIn about a recent article by Radoslaw Kaczmarek, adding:
“Radoslaw (Radek) Kaczmarek just wrote a great commentary about neutralizing anti-AAV antibodies (NAbs) in hemophilia B therapy that can block transduction, thereby abolishing efficacy.
It seems that this is not the case…”
Title: Hemophilia B gene therapy: a NAb-solute barrier overcome by AAV5
Author: Radoslaw Kaczmarek
Read the Full Article on RPTH Journal
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers